-
-
-
-
-
-
-
Amylyx reports early safety data for ALS drug AMX0114
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (AMLX): Grabar Law Office is Investigating Claims on Your Behalf as Securities Fraud Class Action Survives Motion to Dismiss
-
-
-
-
-
-
-
Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis
-
-
-
-
-
-
-
Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia
-
-
-
-
-
-
-
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer
-
-
-
-
-
-
-
Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q2 EPS by 34c
-
-
-
-
-
-
-
AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amylyx
-
1,197,306 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

